ReNerve completes first cases in Hong Kong and Malaysia
Filed with ASX · · 5 pages · English
Summary by 6ix AI
ReNerve Limited has announced the completion of its first surgical cases using the NervAlign® Nerve Cuff in Hong Kong and Malaysia, marking a significant step in its Asia-Pacific commercialization efforts. The company has expanded its regulatory approval in Hong Kong and appointed an exclusive distributor, while also achieving its first surgical case in Malaysia, converting prior market registration into commercial use.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Renerve
- Change in substantial holding - J Chick
- Change of Director's Interest Notice - J Chick
- ReNerve and RMIT awarded $499k grant
- Notice of Annual General Meeting/Proxy Form
- ReNerve - Corporate Governance Statement
Later from Renerve
- ReNerve AGM Presentation
- Results of Meeting
- Notification regarding unquoted securities - RNV
- Proposed issue of securities - RNV
- Application for quotation of securities - RNV
Follow Renerve into a list and get an email when it puts out news.
Follow Renerve